
Human TARP 29-37, FLRNFSLML
Description
About Human TARP 29-37, FLRNFSLML
The Human T-cell receptor gamma alternate reading frame protein Peptide (IEDB: 1863176) is a high quality epitope peptide for stimulation of antigen-specific T cells in T cell assays such as ELISPOT, ICS, cytotoxicity or proliferation assays. The T-cell receptor gamma alternate reading frame protein Peptide, H-FLRNFSLML-OH (Uniprot: A2JGV3 aa: 29-37) from JPT is produced under strict quality control and quality management.
Human TARP 29-37, FLRNFSLML - Specifications
- Peptide sequence: H-FLRNFSLML-OH
- Amount: 1 mg
- Purity: Trial Grade: each peptide purified to > 90% (HPLC/MS)
- Counterion: TFA
- Delivery Format: Freeze-dried in glass vial
- Application(s): T-cell Immunity
- Condition(s)/Topic(s): Prostate cancer, Breast cancer
- Standard Delivery Time: approx. 3 weeks
JPT’s Antigen Peptides
Find your antigen peptide and select the connected PepMix™ Peptide Pool for efficient immune monitoring, mapping of T cell epitopes or development of immunotherapy and vaccines. JPT Peptide Technologies has substantial, long-standing expertise in providing peptides, peptidomimetics, and proteins to the global scientific community. Our highly skilled and committed scientific staff ensures that the most appropriate methods and techniques are selected for every synthesis project. All our catalog peptides are provided with HPLC-MS analyses to confirm the identity and demonstrate the high quality of our peptides.
Not found what you are looking for? Request a Quote for you custom antigen peptide!
Benefits of JPT’s Antigen Peptides
- All peptides are made in Germany
- Bulk orders or custom peptide snythesis upon request
- Synthesis protocols designed to avoid toxic contaminants and side products
- Provision of freeze dried aliquots for enhanced stability
- Proven track record for applications in clinical studies
- Order the connected PepMix™ Peptide Pool with your peptide!
References
References for Human TARP 29-37, FLRNFSLML
References:
Read References with JPT’s Antigen Peptides
Human TARP 29-37, FLRNFSLML has been described in:
TARP vaccination is associated with slowing in PSA velocity and decreasing tumor growth rates in patients with Stage D0 prostate cancer., Oncoimmunology, 2016 (PMID: 27622067)
Human CTLs to wild-type and enhanced epitopes of a novel prostate and breast tumor-associated protein, TARP, lyse human breast cancer cells., Cancer Res, 2004 (PMID: 15059918)
Documentation
Documentation for Human TARP 29-37, FLRNFSLML
Properties
Properties of Human TARP 29-37, FLRNFSLML
Properties | Values |
---|---|
Application: | T-cell immunity |
Category: | Antigen Peptides |
Condition / Topic: | Breast cancer, Prostate cancer |
Layout: | Freeze-dried in glass vial |
Organism: | Human |
Purity: | Trial Grade: each peptide purified to > 90% (HPLC/MS) |
Quantification: | No, Yes |
Further Information to Human TARP 29-37, FLRNFSLML
Information | Values |
---|---|
Sequence: | H-FLRNFSLML-OH |
Specifications: | 9mer peptide as TFA salt |